VYNE and Tay Therapeutics reach licence agreement
2nd May 2023 Uncategorised 0Deal involves an oral BET inhibitor which treats fibrotic and immuno-inflammatory disorders
More: VYNE and Tay Therapeutics reach licence agreement
Source: News
Deal involves an oral BET inhibitor which treats fibrotic and immuno-inflammatory disorders
More: VYNE and Tay Therapeutics reach licence agreement
Source: News
© 1994 - 2026 B.M. Pharmaceuticals